Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $44 to $42.

November 09, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on Revance Therapeutics but lowers the price target from $44 to $42.
The news is directly about Revance Therapeutics. Piper Sandler's decision to maintain an Overweight rating indicates a positive outlook for the company. However, the lowering of the price target from $44 to $42 might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100